San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Swing Therapeutics is raising $9,250,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Rosenbluth played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Swing Therapeutics
Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Its focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription-based digital therapeutic.

To learn more about Swing Therapeutics, visit http://swingtherapeutics.com/

Contact:
Michael Rosenbluth, Chief Executive Officer
619-332-0553
https://www.linkedin.com/in/mikerosenbluth/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved